Mabpharm becomes 100% subsidiary
Cipla announced that Meditab Specialities, a wholly owned subsidiary of the Company, has acquired 75% stake in Mabpharm.The Company was earlier holding 25% stake in Mabpharm. Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100% subsidiary of the Company. Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.
Powered by Capital Market - Live News
